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Abstract: Tryptophan is an essential amino acid that can be metabolised through different pathways, a major route being 
the kynurenine pathway. The ﬁ  rst enzyme of the pathway, indoleamine-2,3-dioxygenase, is strongly stimulated by inﬂ  am-
matory molecules, particularly interferon gamma. Thus, the kynurenine pathway is often systematically up-regulated when 
the immune response is activated. The biological signiﬁ  cance is that 1) the depletion of tryptophan and generation of 
kynurenines play a key modulatory role in the immune response; and 2) some of the kynurenines, such as quinolinic acid, 
3-hydroxykynurenine and kynurenic acid, are neuroactive. The kynurenine pathway has been demonstrated to be involved 
in many diseases and disorders, including Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, AIDS 
dementia complex, malaria, cancer, depression and schizophrenia, where imbalances in tryptophan and kynurenines have 
been found. This review compiles most of these studies and provides an overview of how the kynurenine pathway might 
be contributing to disease development, and the concentrations of tryptophan and kynurenines in the serum, cerebrospinal 
ﬂ  uid and brain tissues in control and patient subjects.
Introduction
Tryptophan is one of the 9 essential amino acids that the human body is incapable of synthesizing and thus, 
has to be obtained through external sources. Once absorbed by the body, tryptophan travels around the 
periphery circulation either bound to albumin or in free form, the two states existing in equilibrium, with 
the former accounting for up to 90%.
1 However, tryptophan can only be transported across the blood brain 
barrier in its free form by the competitive and non-speciﬁ  c L-type amino acid transporter.
2 Once in the 
central nervous system (CNS), tryptophan acts as a precursor to various metabolic pathways. This versa-
tility results in different end-products, such as protein, serotonin and kynurenines.
3 In both the peripheral 
and central systems, the kynurenine pathway represents a major route for the metabolism of tryptophan.
Following the kynurenine pathway (Fig. 1), tryptophan is oxidized by cleavage of the indole-ring, 
initiated either by tryptophan 2,3-dioxygenase (TDO), indoleamine 2,3-dioxygenase 1 (IDO-1) or 
IDO-2, a newly discovered IDO related enzyme.
4–7 TDO resides primarily in the liver and is induced 
by tryptophan or corticosteroids.
4 IDO-1, on the other hand, is the predominant enzyme extra-hepatically 
and can be found in numerous cells, including macrophages, microglia, neurons and astrocytes.
8–11 It 
is up-regulated by certain cytokines and inﬂ  ammatory molecules, such as lipopolysaccharides, amyloid 
peptides and human immunodeﬁ  ciency virus (HIV) proteins,
5,12,13 but its most potent stimulant is inter-
feron gamma (IFN-γ).
14,15 IFN-γ is able to induce both the gene expression and enzymatic activity of 
IDO-1.
16,17 Recently, an IDO related enzyme, IDO-2, was identiﬁ  ed.
7,6 The encoding genes for IDO-1 
and IDO-2 are located next to each other and IDO-2 possesses similar structural and enzymatic activities 
as IDO-1. However, IDO-2 differs in its expression pattern and signalling pathway and is preferentially 
inhibited by D-1-methyl-tryptophan.
7,6
As tryptophan proceeds along the kynurenine pathway to achieve the ﬁ  nal product, nicotinamide 
adenosine dinucleotide (NAD), kynurenine is the ﬁ  rst stable intermediate formed. Subsequently, several 
neuroactive intermediates are generated. These comprise the free-radical generator, 3-hydroxyanthranilic 
acid,
18 the excitotoxin and N-methyl-D-aspartic acid (NMDA) receptor agonist, quinolinic acid,
19 the 
NMDA antagonist, kynurenic acid,
20 and the neuroprotectant, picolinic acid.
21
During an immune response, the release of IFN-γ by activated T cells and leukocytes leads to an 
accelerated and sustained degradation of tryptophan. This signiﬁ  cance was ﬁ  rst speculated to be a defence 2
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mechanism that starved tumour cells, pathogens 
and parasites of tryptophan.
22,23 However, with the 
discovery that IDO-1 activity was necessary for the 
preservation of allogenic fetuses in mice, further 
in vitro research found that tryptophan depletion 
had an anti-proliferative and apoptotic effect on 
T cells.
24–26 In particular, the general control 
non-derepressible-2 (GCN2) kinase was identiﬁ  ed 
as a key mediator in IDO-1 induced tryptophan 
depletion immunosuppression.
27 The activation of 
GCN2 triggers a stress-response program that 
can result in cell-cycle arrest, differentiation, 
adaptation or apoptosis.
28–30 Furthermore, some of 
the kynurenines, such as quinolinic acid and 
3-hydroxyanthranilic acid, can also effectively sup-
press T cell proliferation.
31 This inhibition appears 
to selectively target immune cells undergoing acti-
vation 
32 and these kynurenines may act in concert 
to produce an additive effect.
33 Lastly, the produc-
tion of the excitotoxin quinolinic acid is often 
signiﬁ  cantly increased following inﬂ  ammation and 
resulting immune activation.
34
To date, the kynurenine pathway has been 
implicated in a variety of diseases and disorders, 
including acquired immune deﬁ  ciency syndrome 
(AIDS) dementia complex, Alzheimer’s disease 
(AD), schizophrenia, Huntington’s disease, amyo-
trophic lateral sclerosis (ALS) and neoplasia,
35–43 
and numerous studies have measured the levels of 
tryptophan and kynurenines under those conditions. 
Signiﬁ  cant imbalances in tryptophan and its metab-
olites were frequently observed, which when brought 
back within normal ranges, often resulted in allevia-
tion of symptoms. This review brings together most 
of these studies to provide a better idea of the 
expected differences in tryptophan and kynurenine 
levels in the serum, cerebrospinal ﬂ  uid (CSF) and 
brain between disease and healthy states.
The Kynurenines
Kynurenic acid
Kynurenic acid is an endogenous neuroprotectant 
that is usually present in the brain at nanomolar 
concentrations.
44 An antagonist to quinolinic acid, 
kynurenic acid acts on the glycine modulatory site 
of the NMDA receptor at low concentrations;
45 and 
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Figure 1.  A schematic diagram of the kynurenine pathway.3
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at higher concentrations, at the glutamate site of 
the NMDA receptors and also on the a-amino-
3-hydroxy-5-methyl-4-isoxazolepropionate 
(AMPA) receptors.
46 In addition, it also antago-
nizes the alpha 7 nicotinic acetylcholine receptors
47 
and selectively activates a G-protein coupled 
receptor, GPR35.
48
Increases in brain kynurenic acid were ﬁ  rst 
observed to have sedative and anticonvulsant 
effects.
49 Later, it was found to be protective 
against brain ischemia.
50 The elevation in CSF 
kynurenic acid in schizophrenic patients also 
provided a new insight into the possible effect of 
kynurenic acid on the glutamatergic and dopami-
nergic systems, and its potential role in the 
pathogenesis of schizophrenia.
51,52 Although it is 
argued that the physiological levels of kynurenic 
acid may fall below that which is necessary for 
glutamate receptor antagonism, at speciﬁ  c sites 
within synapses, those levels may be sufﬁ  cient.
53 
This hypothesis is supported by the signiﬁ  cant 
reduction in glutamate release and extracellular 
levels of dopamine seen with kynurenic acid in rats 
in vivo.
54,55 In addition, the use of kynurenine 
3-hydroxylase inhibitor also led to a hyperactivity 
in dopamine neurons.
56
In a septic shock mouse model, kynurenic acid 
was able to signiﬁ  cantly decrease the release of 
tumour necrosis factor α (TNF-α), nitric oxide and 
high mobility group box 1 protein, a molecule 
likely to be involved in lipopolysaccharides 
mediated toxicity.
57,58 Rather unexpectedly though, 
kynurenic acid inhibited the release of ﬁ  broblastic 
growth factor 1, a compound that supports growth 
and recovery of injured cells and enhances 
proliferation of glia cells.
59 However, this does not 
necessarily challenge the concept of kynurenic acid 
being neuroprotective but deﬁ  nitely warrants more 
investigation.
3-hydroxyanthranilic acid
3-hydroxyanthranilic acid can be derived either 
from the hydrolysis of 3-hydroxykyurenine 
or the oxidation of anthranilic acid (Fig. 1). 
Besides playing a role in immunoregulation,
60–62 
3-hydroxyanthranilic acid is also a neurotoxin. 
Intracerebral injection of 3-hydroxyanthranilic acid 
leads to a decrease in choline acetyltransferase 
activity similar to those seen with quinolinic acid, 
but to a lesser extent.
21 In addition, it is a free 
radical (superoxide and hydrogen peroxide) 
generator in the presence of copper.
18 However, 
3-hydroxyanthranilic acid can also act as an 
antioxidant, scavenging peroxyl radicals more 
effectively than equimolar concentrations of either 
ascorbic acid or Trolox (a water soluble analogue 
of vitamin E).
63
In murine macrophages, 3-hydroxyanthranilic 
acid at sub-millimolar concentrations can inhibit 
the activation of nuclear factor κB and likewise, 
the expression and activity of inducible nitric oxide 
synthase (iNOS).
64 iNOS catalyses the formation 
of NO, which is strongly correlated with 
antimicrobial and antitumoral activities in mouse 
macrophages.
65 Following along the lines of 
tumoregenesis, non-toxic concentrations of 
3-hydroxyanthranilic acid has no effect on 
T cell receptor triggered CD8
+ T lymphocyte 
proliferation, but greatly inhibits that induced 
by antigen-independent cytokine (particularly 
interleukin (IL)-2, IL-7 and IL-15) stimulation.
66 
Thus, in the context of cancer, tumour cells could 
severely arrest CD8
+ T cell proliferation by driving 
cytokine production without effectively triggering 
T cell receptor response.
66
Furthermore, 3-hydroxyanthranilic acid exerts 
a selective apoptotic effect on murine thymocytes 
and T helper 1 (Thl) cells via the activation of 
caspase-8 and release of cytochrome c from 
mitochondria, but independent of the Fas pathway.
61 
This action occurs at concentrations well below 
those resulting in neurotoxicity or apoptosis of 
macrophages and could represent an important role 
in peripheral immunoregulation.
61 Adding to this, 
following antigen stimulation of myelin basic 
protein Acl-11 T cell receptor transgenic CD4
+ 
T cells, 3-hydroxyanthranilic acid was associated 
with a Gi/S phase arrest in CD4
+ T cells and a 
cytokine proﬁ  le shift in favour of Th2 cells.
67 This 
ﬁ  nding has important implications in the treatment 
of multiple sclerosis (MS).
67
Picolinic acid
Picolinic acid, a monocarboxylic acid, is an endog-
enous neuroprotectant and a natural iron and zinc 
chelator.
21 It controls cellular growth and has anti-
tumoral, antifungal and antiviral activities. In vitro, 
picolinic acid arrests normal cells in G1 phase, 
possibly through the interactions with NAD
+ as the 
inhibition can be overcome by nicotinamide.
68 
Recently, the characterization of the kynurenine 
pathway in human primary adult neurons and 4
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SK-N-SH neuroblastoma cell line found the former 
capable of synthesizing picolinic acid but not the 
latter.
69 This variation in kynurenine pathway acti-
vation in neuroblastoma cells may provide a key 
to understanding tumour persistence and associated 
neurotoxicity.
In vivo, the antitumoral effect of picolinic acid 
was observed when treatment in mice inoculated 
with MBL-2 lymphoma cells altered their ribo-
somal ribonucleic acid (RNA) metabolism, 
augmenting the cytotoxic and tumoricidal activities 
of macrophages, resulting in increased survival 
rate.
70,71 As an antifungal, picolinic acid acts 
synergistically with IFN-γ to amplify the inhibitory 
effect of neutrophils, inhibiting Candida albicans 
growth in vitro and in vivo.
72,73 Although the mech-
anism of this co-stimulatory effect is unclear, it is 
known to be vulnerable to IL-4 suppression.
74 In 
mouse, the synergy with IFN-γ is further extended 
to include NOS and TNF-α gene expression.
75,76
At relatively high concentrations (1.5–3 mM), 
picolinic acid exerts antiviral, cytotoxic and 
apoptotic effects on HIV-1 and human herpes 
simplex virus-2,
77 which is likely to be associated 
with an up-regulation in macrophage inﬂ  ammatory 
protein (MIP)-1α and MIP-1β messenger RNA 
(mRNA) expression, as both compounds inhibit 
HIV-1 infection.
78–80 Interestingly, this stimulatory 
effect on MlP-lα and β is antagonized by IFN-γ.
81 
The complex interplay between picolinic acid and 
IFN-γ highlights the importance of these molecules 
on the regulation of macrophage activities and 
perhaps, the inﬂ  ammatory response.
81
Like kynurenic acid, picolinic acid blocks 
quinolinic acid induced neurotoxicity, but not the 
neuroexcitatory component.
21,82 Compared to 
kynurenic acid though, picolinic acid is less potent 
and appears to act via a different mechanism, 
attenuating calcium dependent glutamate release 
and/or chelating endogenous zinc.
83,84,85 This lower 
potency of picolinic acid may also be partly 
explained by the weak stimulatory action it has on 
glutamate release from the striatum.
84
Quinolinic acid
Quinolinic acid is a heterocyclic amino acid that 
selectively activates the neuronal NMDA subtype 
of glutamate receptors.
19 Within the brain, quinolinic 
acid concentrations are normally lower compared 
to blood and systemic tissues as tryptophan is 
metabolized to 5-hydroxytryptamine rather than to 
formylkynurenine.
86 However, during an immune 
response, either systemic or central, IDO-1 activity 
and levels of quinolinic acid rise dramatically, the 
signiﬁ  cance of which is still obscure.
87–89
Under inﬂ  ammatory conditions in the brain, 
inﬁ  ltrating macrophages, microglia and dendritic 
cells are major sources of quinolinic acid produc-
tion.
90,91,92 Astrocytes, in contrast, are incapable of 
synthesizing quinolinic acid due to the absence of 
the enzyme, kynurenine hydroxylase.
93 Rather, 
both astrocytes and neurons,
9 being neuroprotective, 
uptake quinolinic acid and catabolize it to NAD. 
However, this catabolic system is easily saturated 
in the presence of high amounts of quinolinic acid, 
produced under pathological conditions, resulting 
in the toxic accumulation of quinolinic acid within 
the cells.
94
As an endogenous molecule of the mammalian 
CNS, the immune and neurotoxic properties of 
quinolinic acid are of special interest.
95 In vitro, 
the synthesis of quinolinic acid by CD8
−” dendritic 
cells induced apoptosis in Thl target cells;
96 and 
quinolinic acid can also selectively inhibit the 
proliferation of CD4
+ and CD8
+ T lymphocytes 
and natural killer cells undergoing activation, the 
effect of which is ampliﬁ  ed in the absence of 
tryptophan.
32
In direct intracerebral administration and 
neuronal cell cultures, quinolinic acid led to neuro-
nal death.
97,98 Similarly, the chronic exposure to 
sub-micromolar concentrations of quinolinic acid 
on neurons produced an adverse effect and the con-
verse was true too.
99,98 In vivo, injection of quino-
linic acid into discrete regions of the rat brain caused 
axon-sparing lesions similar to those produced by 
kainic and ibotenic acid.
97 Several studies have 
already provided strong evidence suggesting that 
quinolinic acid plays a signiﬁ  cant pathological role 
in the development of neurodegenerative disorders, 
such as Huntington’s disease (HD),
99 AD
100,101,102 
and AIDS dementia complex.
103,104,105
The Kynurenine Pathway 
in Disease States
Under various pathological conditions, an acceler-
ated degradation of tryptophan with an accompany-
ing increase in kynurenines is often observed in the 
serum, CSF and/or brain tissue (Tables 1, 2 and 3). 
Moreover, the breakdown of tryptophan via the 
kynurenine pathway is often routed preferen-
tially towards the production of quinolinic acid. 5
Kynurenine pathway metabolites in humans
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The pathologies associated with the up-regulation 
of the kynurenine pathway include infectious 
diseases (e.g. HIV), neurological disorders (e.g. 
AD, HD and ALS), affective disorders (e.g. 
schizophrenia, depression and anxiety), autoim-
mune diseases (e.g. MS and rheumatoid arthritis), 
peripheral conditions (e.g. cardiovascular disease) 
and malignancy (e.g. haematological neoplasia and 
colorectal cancer). However, signiﬁ  cant elevations 
in tryptophan levels in lung and breast cancer have 
also been reported.
106
We also observed an increase in tryptophan 
levels ALS patients’ samples (unpublished). At this 
stage, we speculate that this phenomenon might 
be associated with either a disturbance in albumin 
binding of tryptophan, an over-compensatory 
response to decreased tryptophan concentrations 
in the brain and/or a malfunctioning in the L-type 
amino acid transporter at the blood brain barrier in 
ALS. The elevation in tryptophan notwithstanding, 
ALS patients still exhibited a larger kynurenine/
tryptophan (K/T) ratio, an index for IDO activity, 
than control subjects due to a signiﬁ  cant concomitant 
rise in kynurenine.
The enhanced degradation of tryptophan and 
higher K/T ratio are also often associated with 
advanced stages of disease, more severe symptoms 
or a fatal outcome.
107 108,109 However, it is important 
to note that a progressive increased in tryptophan 
catabolism is part of the “normal” ageing process.
110 
Nonetheless, the degree of tryptophan depletion is 
still far more substantial in neurodegenerative dis-
orders compared to normal ageing and most of the 
studies on pathological conditions were performed 
using age matched control subjects.
111,100
In some studies, neopterin concentrations were also 
measured. Neopterin is a marker for immune activa-
tion and show a correlation with the K/T ratio and 
kynurenine, and inversely with tryptophan.
112,113,87 This 
suggests an increase in endogenous IFN-γ  production 
and an up-regulation in the kynurenine pathway. 
Indeed, HIV patients exhibit a 10-fold increase in 
IFN-γ through direct measurements.
114
When HIV patients are treated with highly active 
antiretroviral therapy (HAART) or antiretroviral 
treatment (ART), which signiﬁ  cantly decreases 
immune activation through reduction in viral load, 
a repletion in tryptophan and reduction in kynuren-
ine and quinolinic acid often follows.
115,116 It is 
interesting to note that the alteration in tryptophan 
levels occurred in the absence of any dietary 
modiﬁ  cation and that changes in K/T ratio correlated 
A
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strongly with HIV mRNA and CD4
+ T cell 
count.
116
The most important consequences of dramatic 
decline in tryptophan, thus, are likely to be 
immunosuppression and immunodeficiency, 
particularly evident in HIV infection, but also in 
autoimmune diseases and cancer. Other effects 
include weight loss, mood disturbances and cogni-
tive impairment.
117,118
In anorexia nervosa, underweight anorexic 
patients had lower tryptophan levels which rose 
with weight normalization.
117 The association of 
tryptophan levels and the development of cachexia 
and weight loss are also evident in neoplasia.
119,120 
This could be associated with the release of pro-
inﬂ  ammatory cytokines. TNF-α, for instance, is a 
known cachexia, featuring prominently in muscle 
pathophysiology.
121 The heightened catabolism of 
tryptophan via the kynurenine pathway may also 
divert this essential amino acid away from protein 
synthesis, thus, contributing to weight loss and 
muscle wasting.
119
Tryptophan also acts as a precursor for the 
synthesis of serotonin, which has a broad spectrum 
of action, two of which are in mood and cognitive 
functioning.
118,122 Imbalances in kynurenines and 
significant decline in 5-hydroxyindoleacetic 
acid (5-HIAA), a serotonin metabolite, have 
been reported in major depression, MS and 
cardiovascular disease, among others.
123,124,125 
However, the activation of the immune response 
is also postulated as a cause of depression
126,127 
and a strong association exists between inﬂ  amma-
tory diseases and depression.
128,129
In normal subjects, the deliberate depletion 
of tryptophan selectively impaired long-term 
memory consolidation,
130 opposed to the results 
observed with the administration of selective 
serotonin reuptake inhibitors.
131 In AD and HD 
patients, the K/T ratio was also inversely corre-
lated with cognitive performance;
132,133 and in 
HIV-1 patients, treatment with HAART, which 
elevates tryptophan levels, markedly improved 
cognitive function.
134,135
Potential Treatments Involving 
the Kynurenine Pathway
The involvement of the kynurenine pathway in a 
wide range of diseases suggests that research on 
treatment strategies targeting the kynurenine 
pathway (Fig. 2) may provide an alternative means 
of treatment or as a complement to what is already 
available.
Niacin supplementation
One of the consequences of accelerated degradation 
and depletion of tryptophan in the body is the 
Tryptophan
IDO
KYNU
NAD
1-methyl tryptophan
Methyl-thiohydantion-tryptophan
Leflunomide
: Analogue
Negative
feedback
Teriflunomide
4-chlorokynurenine
Laquinimod
Nicotinylalanine
Meta-nitrobenzoylalanine
Ro61-8048
Tranilast
Formylkynurenine
Kynurenic acid Kynurenine
3-hydroxykynurenine
3-hydroxyanthranilic acid
Picolinic acid
Quinolinic acid
X
X
Figure 2. Drugs targeting the kynurenine pathway—inhibitors and analogues.14
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suppression of T cell proliferation,
136 which 
compromises the body’s immunity. Repletion of 
tryptophan could lead to improve immune response 
but may also inadvertently cause an increase in 
neurotoxins. Niacin supplementation, however, 
provides an indirect way to increase tryptophan 
and act as a feedback mechanism to suppress 
IDO-1 activity.
137 In clinical studies, dietary 
supplementation of niacin to HIV-1 patients was 
associated with higher CD4 counts and improved 
survival rates.
138,139
IDO inhibitors
The suppression of IDO-1 activity has been targeted 
directly in cancer research. Using transgenic mouse 
model of breast cancer, IDO-1 inhibitors, 1-methyl-
DL-tryptophan and methyl-thiohydantoin-
tryptophan, were able to potentiate the efﬁ  cacy of 
chemotherapy drugs, promoting tumour regression 
without increasing the side effects.
140 The discovery 
of the preferential inhibition by D-l-methyl-
tryptophan on IDO-2 could also provide the key to 
understanding the mechanism behind the antitumoral 
action of 1-methyl-tryptophan and in designing 
future IDO inhibitors.
7
Kynurenine analogues
Another approach to modifying the kynurenine 
pathway is to skew the balance of kynurenines 
towards neuroprotection and away from neurotox-
icity. Currently, there are several therapeutic agents, 
either already on the market or undergoing clinical 
trials, which are either analogues of neuroprotective 
kynurenines or act to inhibit the production of 
quinolinic acid. They include 4-chlorokynurenine, 
laquinimod, leﬂ  unomide, tranilast, nicotinylalanine, 
meta-nitrobenzoylalanine and Ro61-8048.
7-chlorokynurenate, a synthetic derivative 
of kynurenic acid, attenuates the neurotoxic effect 
of quinolinic acid through blockade of the glycine 
modulatory site of the NMDA receptor.
141,142 
However, 7-chlorokynurenate crosses the blood brain 
barrier with great difﬁ  culty.
143 4-chlorokynurenine, 
a precursor of 7-chlorokynurenate, on the other 
hand, is able to overcome this obstacle.
144 
When administered together with quinolinic acid 
in vivo, 4-chlorokynurenine was converted into the 
active 7-chlorokynurenate successfully, providing 
neuroprotection.
145,146
Laquinimod (ABR-215062), a novel synthetic 
quinoline, has demonstrated immunomodulatory 
properties without immunosuppression in preclinical 
trials.
147–149 In MS animal model, experimental 
autoimmune encephalomyelitis (EAE), laquinimod 
delayed disease progression, inhibited inﬁ  ltration of 
CD4
+ T cells and macrophages into the CNS and 
modulated the immune response in favour of Th2/Th3 
cytokines IL-4, IL-10 and transforming growth factor 
(TGF-P).
150 Furthermore, in patients with relapsing 
MS, treatment with laquinimod successfully reduced 
the development of active lesions.
151
Leﬂ  unomide (Avara
®), an immunosuppressive 
and anti-inﬂ  ammatory prodrug is converted into 
terﬂ  unomide in vivo (A771126). Terﬂ  unomide is 
an inhibitor of mitochondrial dihydroorotate 
dehydrogenase, an essential enzyme for de novo 
pyrimidine synthesis.
152 In 1998, the Food and 
Drug Administration (FDA, U.S.A.) approved 
leflunomide for the treatment of rheumatoid 
arthritis. Furthermore, in a recent phase II trial with 
MS patients, terﬂ  unomide proved well tolerated 
and effective in reducing active lesions.
153
Tranilast (Rizaben
®), a synthetic anthranilic 
acid derivative drug, has the ability to inhibit the 
release of chemical mediators, TGF-É¿ and sup-
press angiogenesis.
154,155 Tranilast has been effec-
tive against many diseases, such as allergic rhinitis, 
atopic dermatitis and bronchial asthma. Recently, 
when tested against EAE, tranilast inhibited the 
actions of Thl cells while enhancing those of Th2 
cells, an action similar to that of natural tryptophan 
catabolites, 3-hydroxyanthranilic acid and 
3-hydroxykynurenic acid.
67
Finally, kynurenine hydroxylase inhibitors are 
also effective in diverting the kynurenine pathway 
away from the synthesis of quinolinic acid towards 
that of kynurenic acid. These compounds include 
nicotinylalanine, meta-nitrobenzoylalanine and 
Ro61-8048.
156 Nicotinylalanine, an analogue of 
kynurenine, protects the brain from induced 
seizures
157,158 and quinolinic acid induced striatal 
damage in the rat.
159 With meta-nitrobenzoylalanine, 
sedation and anticonvulsant effects were achieved 
in rats,
160 while reduced neuronal loss from brain 
ischemia were seen in gerbils.
50 In immune activated 
mice, meta-nitronemzoylalanine also signiﬁ  cantly 
decreased quinolinic acid production in the blood 
and brain.
161 With Ro61-8048, there is an additional 
benefit of reducing glutamate levels in the 
extracellular spaces of the basal ganglia in 
rats, while maintaining the learning and memory 
process.
162 In EAE rats, administration of Ro61-8048 
significantly reduced the neurotoxic levels 15
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of 3-hydroxykynurenine and quinolinic acid in the 
CNS;
163 and in a cerebral malaria mouse model, it 
signiﬁ  cantly increased the neuroprotective levels of 
picolinic acid, prevented the development of neu-
rological symptoms and prolonged survival by 
threefold.
164 Like meta-nitrobenzoylalanine, 
Ro61-8048 too decreased neuronal loss due to brain 
ischemia.
50
Conclusion
The kynurenine pathway is an effective mechanism 
in modulating the immune response and in inducing 
immune tolerance. This is achieved by accelerating 
the degradation of tryptophan and the generation 
of kynurenines. The metabolites of the pathway, 
with their different inherent properties, can also 
synergize or antagonize the effects of one another. 
By measuring the levels of tryptophan, kynurenines 
and the K/T ratio under various pathological con-
ditions, the degree of immune activation and the 
relationship between the kynurenine pathway and 
disease states may be gleaned. However, much 
research is still needed to fully understand the 
complex interaction between tryptophan, IDO and 
kynurenines among themselves and within the 
CNS and in the periphery. With the seemingly 
prevalent involvement of the kynurenine pathway 
in a wide range of different diseases and disorders, 
the knowledge gained from research focusing on 
the kynurenine pathway may be translated into 
designing novel and more effective treatment 
strategies.
Acknowledgements
This study was funded by the Motor Neuron Disease 
Research Institute Association (Australia).
Disclosure
The authors report no conﬂ  icts of interest.
References
  1.  Mcmenamy RH. Binding of indole analogues to human serum albumin. 
Effects of fatty acids. J Biol Chem. 1965;240:4235–43.
  2.  Hargreaves KM, Pardridge WM. Neutral amino acid transport at the 
human blood-brain barrier. J Biol Chem. 1988;263:19392–7.
  3.  Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, Lowry CA. 
Tryptophan metabolism in the central nervous system: medical 
implications. Expert Rev Mol Med. 2006;8:1–27.
 4.  Salter M, Pogson CI. The role of tryptophan 2,3-dioxygenase in the 
hormonal control of tryptophan metabolism in isolated rat liver cells. 
Effects of glucocorticoids and experimental diabetes. Biochem J. 
1985;229:499–504.
 5.  Takikawa O. Biochemical and medical aspects of the indoleamine 
2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys 
Res Commun. 2005;338:12–9.
 6.  Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an 
indoleamine 2,3-dioxygenase-like protein found in humans and mice. 
Gene. 2007;396:203–13.
 7.  Metz R, Duhadaway JB, Kamasani U, Laury-kleintop L, Muller AJ, 
Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the 
preferred biochemical target of the antitumor indoleamine 2,3-dioxy-
genase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 
2007;67:7082–7.
 8.  Guillemin GJ, Smythe G, Takikawa O. Brew BJ. Expression of 
indoleamine 2,3-dioxygenase and production of quinolinic acid by 
human microglia, astrocytes, and neurons. Glia. 2005d;49:15–23.
  9.  Guillemin GJ, Cullen KM, Lim, CK, et al. Characterization of the Kynurenine 
Pathway in Human Neurons. J Neuro sci. 2007b;27:12884–92.
10.  Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway metab-
olism in human astrocytes: a paradox for neuronal protection. J Neuro 
chem. 2001;78:1–13.
11.  Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ. Expression 
of the kynurenine pathway enzymes in human microglia and 
macrophages. Adv Exp Med Biol. 2003a;527:105–12.
12.  Fujigaki S, Saito K, Sekikawa K, et al. Lipopolysaccharide induction of 
indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-
independent mechanism. Eur J Immunol. 2001;31:2313–8.
13.  Guillemin GJ, Smythe GA, Veas LA, Takikawa O, Brew BJ. A beta 
1–42 induces production of quinolinic acid by human macrophages 
and microglia. Neuroreport. 2003b;14:2311–5.
14.  Hayaishi O, Yoshida R. Speciﬁ  c induction of pulmonary indoleamine 
2,3-dioxygenase by bacterial lipopolysaccharide. Ciba Found Symp. 
1978;199–203.
15.  Werner-felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, 
Wachter H. Characteristics of interferon induced tryptophan 
metabolism in human cells in vitro. Biochim Biophys Acta. 
1989;1012:140–7.
16. Yasui H, Takai K, Yoshida R, Hayaishi O. Interferon enhances tryptophan 
metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its 
possible occurrence in cancer patients. Proc Natl Acad Sci U S A. 
1986;83:6622–6.
17.  Dai W, Gupta SL. Regulation of indoleamine 2,3-dioxygenase gene 
expression in human ﬁ  broblasts by interferon-gamma. Upstream con-
trol region discriminates between interferon-gamma and interferon-
alpha. J Biol Chem. 1990;265:19871–7.
18.  Goldstein LE, Leopold MC, Huang X, et al. 3-Hydroxykynurenine and 
3-hydroxyanthranilic acid generate hydrogen peroxide and promote 
alpha-cry stallin cross-linking by metal ion reduction. Biochemistry. 
2000;39:7266–75.
19.  Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant 
at amino acid receptors in CNS. Eur J Pharmacol. 1981;72:411–2.
20.  Perkins MN, Stone TW. An iontophoretic investigation of the actions 
of convulsant kynurenines and their interaction with the endogenous 
excitant quinolinic acid. Brain Res. 1982;247:184–7.
21.  Jhamandas K, Boegman RJ, Beninger RJ, Bialik M. Quinolinate-
induced cortical cholinergic damage: modulation by tryptophan 
metabolites. Brain Res. 1990;529:185–91.
22.  Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. 
Implications of interferon-induced tryptophan catabolism in cancer, auto-
immune diseases and AIDS. Adv Exp Med Biol. 1991;94:425–35.
23.  Pfefferkorn ER. Interferon gamma blocks the growth of Toxoplasma 
gondii in human ﬁ  broblasts by inducing the host cells to degrade 
tryptophan. Proc Natl Acad Sci U S A. 1984;81:908–12.
24.  Lee, GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. 
Tryptophan deprivation sensitizes activated T cells to apoptosis prior 
to cell division. Immunology. 2002;107:452–60.
25. Munn  DH,  Shaﬁ  zadeh E, Attwood JT, Bondarev I, Pashine A, Mellor 
AL. Inhibition of T cell proliferation by macrophage tryptophan 
catabolism. J Exp Med. 1999;189:1363–72.16
Chen and Guillemin
International Journal of Tryptophan Research 2009:2 
26.  Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal 
rejection by tryptophan catabolism. Science. 1998;281:1191–3.
27.  Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells medi-
ates proliferative arrest and anergy induction in response to indoleamine 
2,3-dioxygenase. Immunity. 2005;22:633–42.
28.  Rao RV, Ellerby HM, Bredesen DE. Coupling endoplasmic reticulum 
stress to the cell death program. Cell Death Differ. 2004;11:372–80.
29.  De haro C, Mendez R, Santoyo J. The eIF-2alpha kinases and the 
control of protein synthesis. Faseb J. 1996;10:1378–87.
30.  Bi M, Naczki C, Koritzinsky M, et al. ER stress-regulated translation 
increases tolerance to extreme hypoxia and promotes tumor growth. 
Embo J. 2005;24:3470–81.
31.  Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by kynuren-
ines. Adv Exp Med Biol. 2003;527:183–90.
32.  Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. 
Tryptophan-derived catabolites are responsible for inhibition of T and 
natural killer cell proliferation induced by indoleamine 2,3-dioxygen-
ase. J Exp Med. 2002;196:459–68.
33.  Terness P, Bauer TM, Rose L, et al. Inhibition of allogeneic T cell 
proliferation by indoleamine 2,3-dioxygenase-expressing dendritic 
cells: mediation of suppression by tryptophan metabolites. J Exp Med. 
2002;196:447–57.
34.  Moffett JR, Els T, Espey MG, Walter SA, Streit WJ, Namboodiri MA. 
Quinolinate immunoreactivity in experimental rat brain tumors is present 
in macrophages but not in astrocytes. Exp Neurol. 1997;144:287–301.
35.  Guillemin G, Brew BJ. Implications of the kynurenine pathway and 
quinolinic acid in Alzheimer’s disease. Redox Rep. 2002;7:199–206.
36.  Guillemin G, Meininger V, Brew B. Implications for the kynurenine 
pathway and quinolinic acid in amyotrophic lateral sclerosis. Neuro-
degenerative diseases. 2006;2:166–76.
37.  Guillemin GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in 
AIDS dementia complex. Neurotox Res. 2005c;7:103–23.
38.  Ting K, Brew BJ, Guillemin GJ. Effect of quinolinic acid on gene 
expression in human astrocytes: Implications for Alzheimer’s disease. 
In: Takai K. (ed.) International Congress Series. 2007.
39.  Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms 
involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 
2004;27:723–49.
40.  Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED. Kynurenine 
pathway measurements in Huntington’s disease striatum: evi-
dence for reduced formation of kynurenic acid. J Neurochem. 
1990;55:1327–39.
41.  LIM, CK, Smythe GA, Stocker R, Brew BJ, Guillemin GJ. 
Characterization of the kynurenine pathway in human oligodendrocytes. 
In: Takai K. (ed.) International Congress Series. 2007.
42.  Stoy N, Mackay GM, Forrest CM, et al. Tryptophan metabolism and 
oxidative stress in patients with Huntington’s disease. J Neurochem. 
2005;93:611–23.
43.  Zamanakou M, Germenis AE, Karanikas V. Tumor immune escape medi-
ated by indoleamine 2,3-dioxygenase. Immunol Lett. 2007;111:69–75.
44. Moroni  F,  Russi P, Lombardi G, Beni M, Carla V. Presence of kynurenic 
acid in the mammalian brain. J Neurochem. 1988;51:177–80.
45.  Stone TW. Neuropharmacology of quinolinic and kynurenic acids. 
Pharmacol Rev. 1993;45:309–79.
46.  Stone TW, Addae JI. The pharmacological manipulation of glutamate 
receptors and neuroprotection. Eur J Pharmacol. 2002;447:285–96.
47.  Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, 
Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 
nicotinic receptor activity and increases non-alpha7 nicotinic recep-
tor expression: physiopathological implications. J Neuro Sci. 
2001;21:7463–73.
48.  Wang H, Liao H, Ochani M, et al. Cholinergic agonists inhibit HMGB1 
release and improve survival in experimental sepsis. Nat Med. 
2004;10:1216–21.
49.  Carpenedo R, Chiarugi A, Russi P, et al. Inhibitors of kynurenine 
hydroxylase and kynureninase increase cerebral formation of kynure-
nate and have sedative and anticonvulsant activities. Neuro Science. 
1994;61:237–43.
50.  Cozzi A, Carpenedo R, Moroni F. Kynurenine hydroxylase inhibitors 
reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine 
(mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]- benzene-
sulfonamide (Ro 61–8048) in models of focal or global brain ischemia. 
J Cereb Blood Flow Metab. 1999;19:771–7.
51.  Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. 
Kynurenic acid levels are elevated in the cerebrospinal ﬂ  uid of patients 
with schizophrenia. Neurosci Lett. 2001;33:96–8.
52.  Grace AA. Phasic versus tonic dopamine release and the modulation 
of dopamine system responsivity: a hypothesis for the etiology of 
schizophrenia. Neuroscience. 1991;41:1–24.
53. Scharfman HE, Goodman JH, Schwarcz R. Electrophysiological effects 
of exogenous and endogenous kynurenic acid in the rat brain: studies 
in vivo and in vitro. Amino Acids. 2000;19:283–97.
54.  Carpenedo R, Pittaluga A, Cozzi A, et al. Presynaptic kynurenate-sensitive 
receptors inhibit glutamate release. Eur J Neurosci. 2001;13:2141–7.
55. Rassoulpour A, Wu HQ, Ferre S, Schwarcz R. Nanomolar concentrations 
of kynurenic acid reduce extracellular dopamine levels in the striatum. 
J Neurochem. 2005;93:762–5.
56.  Erhardt S, Oberg H, Mathe JM, Engberg G. Pharmacological elevation 
of endogenous kynurenic acid levels activates nigral dopamine neurons. 
Amino Acids. 2001b;20:353–62.
57.  Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment 
of sepsis. Nat Med. 2003;9:517–24.
58.  Moroni F, Fossati S, Chiarugi A, Cozzi A. Kynurenic acid actions in brain 
and periphery. International Congress Series. 2007;1304:305–13.
59.  Serio CD, Cozzi A, Angeli I, et al. Kynurenic acid inhibits the release 
of the neurotrophic ﬁ  broblast growth factor (FGF)-l and enhances 
proliferation of glial cells, in vitro. Cell Mol Neurobiol. 2005.
60. Morita T, Saito K, Takemura M, et al. 3-Hydroxyanthranilic acid, an L-tryp-
tophan metabolite, induces apoptosis in monocyte-derived cells stimulated 
by interferon-gamma. Ann Clin Biochem. 2001;38:242–51.
61.  Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan 
catabolism. Cell Death Differ. 2002;9:1069–77.
62. Lopez AS, Alegre E, Diaz-lagares A, Garcia-giron C, Coma MJ, 
Gonzalez A. Effect of 3-hydroxyanthranilic acid in the immunosup-
pressive molecules indoleamine dioxygenase and HLA-G in 
macrophages. Immunol Lett. 2008;117:91–5.
63.  Christen S, Peterhans E, Stocker R. Antioxidant activities of some 
tryptophan metabolites: possible implication for inﬂ  ammatory diseases. 
Proc Natl Acad Sci U S A. 1990;87:2506–10.
64.  Sekkai D, Guittet O, Lemaire G, Tenu JP, Lepoivre M. Inhibition of 
nitric oxide synthase expression and activity in macrophages by 
3-hydroxyanthranilic acid, a tryptophan metabolite. Arch Biochem 
Biophys. 1997;340:117–23.
65.  Nathan CF, Hibbs JB Jr. Role of nitric oxide synthesis in macrophage 
antimicrobial activity. Curr Opin Immunol. 1991;3:65–70.
66.  Weber WP, Feder-mengus C, Chiarugi A, et al. Differential effects of 
the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation 
of human CD8+ T cells induced by TCR triggering or homeostatic 
cytokines. Eur J Immunol. 2006;36:296–304.
67.  Platten M, Ho PP, Youssef S, et al. Treatment of autoimmune neuroinﬂ  am-
mation with a synthetic tryptophan metabolite. Science. 2005;310:850–5.
68.  Fernandez-pol, JA, Bono VH, Johnson GS. Control of growth by 
picolinic acid: differential response of normal and transformed cells. 
Proc Natl Acad Sci U S A. 1977;74:2889–93.
69.  Guillemin GJ, Cullen KM, Lim CK, et al. Characterization of the kyn-
urenine pathway in human neurons. J Neurosci. 2007c;27:12884–92.
70.  Varesio L, Clayton M, Blasi E, Ruffman R, Radzioch D. Picolinic acid, 
a catabolite of tryptophan, as the second signal in the activation of 
IFN-gamma-primed macrophages. J Immunol. 1990;145:4265–71.
71. Ruffmann R, Schlick R, Chirigos MA, Budzynsky W, Varesio L. 
Antiproliferative activity of picolinic acid due to macrophage activation. 
Drugs Exp Clin Res. 1987;13:607–14.
72. Abe  S,  Hu W, Ishibashi H, Hasumi K, Yamaguchi H. Augmented 
inhibition of Candida albicans growth by murine neutrophils in the 
presence of a tryptophan metabolite, picolinic acid. J Infect Chemother. 
2004;10:181–4.17
Kynurenine pathway metabolites in humans
International Journal of Tryptophan Research 2009:2 
73.  Blasi E, Mazzolla R, Pitzurra L, Barluzzi R, Bistoni F. Protective effect 
of picolinic acid on mice intracerebrally infected with lethal doses of 
Candida albicans. Antimicrob Agents Chemother. 1993;37:2422–6.
74.  Cox GW, Chattopadhyay U, Oppenheim JJ, Varesio L. IL-4 inhibits the 
costimulatory activity of IL-2 or picolinic acid but not of lipopolysaccharide 
on IFN-gamma-treated macrophages. J Immunol. 1991;147:3809–14.
75.  Melillo G, Cox GW, Biragyn A, Shefﬂ  er LA, Varesio L. Regulation of 
nitric-oxide synthase mRNA expression by interferon-gamma and 
picolinic acid. J Biol Chem. 1994;269:8128–33.
76.  Pais TF, Appelberg R. Macrophage control of mycobacterial growth 
induced by picolinic acid is dependent on host cell apoptosis. J Immunol. 
2000;164:389–97.
77.  Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a Rantes 
MIP-1 alpha, MlP-lbeta receptor as a fusion cofactor for macrophage-
tropic HIV-1. Science. 1996;272:1955–8.
78.  Fernandez-pol JA, Klos DJ, Hamilton PD. Antiviral cytotoxic and 
apoptotic activities of picolinic acid on human immunodeﬁ  ciency 
virus-1 and human herpes simplex virus-2 infected cells. Anticancer 
Res. 2001;21:3773–6.
79.  Bosco MC, Rapisarda A, Massazza S, Melillo G, Young H, Varesio L. 
The tryptophan catabolite picolinic acid selectively induces the che-
mokines macrophage inﬂ  ammatory protein-1 alpha and -1 beta in 
macrophages. J Immunol. 2000;164:3283–91.
80.  Cocchi F, Devico AL, Garzino-demo A, Arya SK, Gallo RC, Lusso P. 
Identiﬁ  cation of Rantes MIP-1 alpha, and MIP-1 beta as the major 
HIV-suppressive factors produced by CD8+ T cells. Science. 
1995;270:1811–5.
81.  Rapisarda A, Pastorino S, Massazza S, Varesio L, Bosco MC. Antago-
nistic effect of picolinic acid and interferon-gamma on macrophage 
inflammatory protein-1 alpha/beta production. Cell Immunol. 
2002;220:70–80.
82.  Beninger RJ, Colton AM, Ingles JL, Jhamandas K, Boegman RJ. 
Picolinic acid blocks the neurotoxic but not the neuroexcitant proper-
ties of quinolinic acid in the rat brain: evidence from turning behaviour 
and tyrosine hydroxylase immunohistochemistry. Neuroscience. 
1994;61:603–12.
83.  Jhamandas KH, Boegman RJ, Beninger RJ, Flesher S. Role of zinc in 
blockade of excitotoxic action of quinolinic acid by picolinic acid. 
Amino Acids. 1998;14:257–61.
84.  Vrooman L, Jhamandas K, Boegman RJ, Beninger RJ. Picolinic acid 
modulates kainic acid-evoked glutamate release from the striatum in vitro. 
Brain Res. 1993;627:193–8.
85.  Cockhill J, Jhamandas K, Boegman RJ, Beninger RJ. Action of 
picolinic acid and structurally related pyridine carboxylic acids on 
quinolinic acid-induced cortical cholinergic damage. Brain Res. 
1992;599:57–63.
86. Heyes  MP, Chen CY, Major EO, Saito K. Different kynurenine pathway 
enzymes limit quinolinic acid formation by various human cell types. 
Biochem J. 1997;326(Pt 2):351–6.
87.  Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine 
pathway metabolism in inﬂ  ammatory and non-inﬂ  ammatory neuro-
logical disease. Brain. 1992;115(Pt 5):1249–73.
88.  Flanagan EM, Erickson JB, Viveros OH, Chang SY, Reinhard JF Jr. 
Neurotoxin quinolinic acid is selectively elevated in spinal cords of 
rats with experimental allergic encephalomyelitis. J Neurochem. 
1995;64:1192–6.
89.  Espey MG, Tang Y, Morse HC 3rd, Moffett JR, Namboodiri MA. 
Localization of quinolinic acid in the murine AIDS model of retrovirus-
induced immunodeﬁ  ciency: implications for neurotoxicity and dendritic 
cell immunopathogenesis. Aids. 1996;10:151–8.
90.  Brew BJ, Corbeil J, Pemberton L, et al. Quinolinic acid production is related 
to macrophage tropic isolates of HIV-1. J Neurovirol. 1995;1:369–74.
91.  Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP. 
Human microglia convert 1-tryptophan into the neurotoxin quinolinic 
acid. Biochem J. 1996;320(Pt 2):595–7.
92.  Moffett JR, Espey MG, Gaudet SJ. Namboodiri MA. Antibodies to 
quinolinic acid reveal localization in select immune cells rather than 
neurons or astroglia. Brain Res. 1993;623:337–40.
  93.  Guillemin GJ, Smith DG, Kerr SJ, et al. Characterisation of kynuren-
ine pathway metabolism in human astrocytes and implications in 
neuropathogenesis. Redox Report. 2000;5:108–11.
 94.  Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. 
Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity 
in Alzheimer’s disease hippocampus. Neuropathol Appl Neurobiol. 
2005a;31:395–404.
  95.  Wolfensberger M, Amsler U, Cuenod M, Foster AC, Whetsell WO 
Jr. Schwarcz R. Identiﬁ  cation of quinolinic acid in rat and human 
brain tissue. Neurosci Lett. 1983;41:247–52.
  96.  Belladonna ML, Grohmann U, Guidetti P, et al. Kynurenine pathway 
enzymes in dendritic cells initiate tolerogenesis in the absence of 
functional IDO. J Immunol. 2006;111:130–7.
 97.  Schwarcz R, Whetsell WO Jr, Mangano RM. Quinolinic acid: an 
endogenous metabolite that produces axon-sparing lesions in rat 
brain. Science. 1983;219:316–8.
  98.  Kim JP, Choi DW. Quinolinate neurotoxicity in cortical cell culture. 
Neuroscience. 1987;23:423–32.
  99.  Whetsell WO Jr, Schwarcz R. Prolonged exposure to submicromolar 
concentrations of quinolinic acid causes excitotoxic damage in 
organotypic cultures of rat corticostriatal system. Neurosci Lett. 
1989;97:271–5.
100.  Widner B, Leblhuber F, Fuchs D. Increased neopterin production and 
tryptophan degradation in advanced Parkinson’s disease. J Neural 
Transm. 2002;109:181–9.
101. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. 
Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity 
in Alzheimer’s disease hippocampus. Neuropathol Appl Neurobiol. 
2005b;31:395–404.
102.  Guillemin GJ, Brew BJ, Noonan CE, Knight TG, Smythe GA, 
Cullen KM. Mass spectrometric detection of quinolinic acid in 
microdissected Alzheimer’s disease plaques. In: Takai K. (Ed.) 
International Congress Series. 2007a.
103.  Heyes MP, Brew BJ, Martin A, Markey SP, Price RW, Bhalla RB, 
Salazar A. Cerebrospinal ﬂ  uid quinolinic acid concentrations are 
increased in acquired immune deﬁ  ciency syndrome. Adv Exp Med 
Biol. 1991a;294:687–90.
104.  Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebrospinal 
ﬂ  uid and serum in HIV-1 infection: relationship to clinical and neu-
rological status. Ann Neurol. 1991b ;29:202–9.
105.  Guillemin GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in 
ADDS dementia complex. Neurotox Res. 2004;7:103–24.
106.  Cascino A, Cangiano C, Ceci F, et al. Increased plasma free tryptophan 
levels in human cancer: a tumor related effect? Anticancer Research. 
1991;11:1313–6.
107.  Schroecksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M, 
Fuchs D. Tryptophan degradation increases with stage in patients 
with rheumatoid arthritis. Clin Rheumatol. 2006;25:334–7.
108.  Giusti RM, Maloney EM, Hanchard B, et al. Differential patterns of 
serum biomarkers of immune activation in human T-cell lymphotropic 
virus type I-associated myelopathy/tropical spastic paraparesis, and 
adult T-cell leukemia/lymphoma. Cancer Epidemiol Biomarkers Prev. 
1996;5:699–704.
109.  Medana IM, Day NP, Salahifar-sabet H, et al. Metabolites of the kyn-
urenine pathway of tryptophan metabolism in the cerebrospinal ﬂ  uid 
of Malawian children with malaria. J Infect Dis. 2003;188:844–9.
110.  Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. 
Increasing production of homocysteine and neopterin and degradation 
of tryptophan with older age. Clin Biochem. 2004;37:684–7.
111.  Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, 
Roberts RC. Increased cortical kynurenate content in schizophrenia. 
Biol Psychiatry. 2001;50:521–30.
112.  Murr C, Gerlach D, Widner B, Dierich MP, Fuchs D. Neopterin pro-
duction and tryptophan degradation in humans infected by Streptococcus 
pyogenes. Med Microbiol Immunol. 2001;189:161–3.
113.  Schroecksnadel K, Winkler C, Fuith LC, Fuchs D. Tryptophan deg-
radation in patients with gynecological cancer correlates with immune 
activation. Cancer Lett. 2005;223:323–9.18
Chen and Guillemin
International Journal of Tryptophan Research 2009:2 
114.  Fuchs D, Moller AA, Reibnegger G, Werner ER, Werner-felmayer G, 
Dierich MP, Wachter H. Increased endogenous interferon-gamma 
and neopterin correlate with increased degradation of tryptophan in 
human immunodeﬁ  ciency virus type 1 infection. Immunol Lett. 
1991;28:207–11.
115.  Look MP, Altfeld M, Kreuzer KA, et al. Parallel decrease in neuro-
toxin quinolinic acid and soluble tumor necrosis factor receptor p75 
in serum during highly active antiretroviral therapy of HIV type 1 
disease. AIDS Res Hum Retroviruses. 2000;16:1215–21.
116.  Zangerle R, Widner B, Quirchmair G, Neurauter G, Sarcletti M, Fuchs D. 
Effective antiretroviral therapy reduces degradation of tryptophan in 
patients with HIV-1 infection. Clin Immunol. 2002;104:242–7.
117.  Demitrack MA, Heyes MP, Altemus M, Pigott TA, Gold PW. Cere-
brospinal ﬂ  uid levels of kynurenine pathway metabolites in patients 
with eating disorders: relation to clinical and biochemical variable. 
Biol Psychiatry. 1995;37:512–20.
118.  Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ. Serotonin 
and human cognitive performance. Curr Pharm Des. 2006;12:2473–86.
119.  Iwagaki H, Hizuta A, Tanaka N, Orita K. Decreased serum tryptophan 
in patients with cancer cachexia correlates with increased serum 
neopterin. Immunol Invest. 1995;24:467–78.
120.  Denz H, Orth B, Weiss G, Herrmann R, Huber P, Wachter H, 
Fuchs D. Weight loss in patients with hematological neoplasias is 
associated with immune system stimulation. Clin Investig. 
1993;71:37–41.
121.  Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis 
factor and the macrophage-secreted factor cachectin. Nature. 
1985;316:552–4.
122.  Riedel WJ, Klaassen T, Schmitt JA. Tryptophan mood, and cognitive 
function. Brain Behav Immun. 2002;16:581–9.
123. Myint AM, Kim YM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. 
Kynurenine pathway in major depression: evidence of impaired 
neuroprotection. J Affect Disord. 2007;98:143–51.
124.  Maes M, Scharpe S, Meltzer HY, et al. Increased neopterin and 
interferon-gamma secretion and lower availability of L-tryptophan 
in major depression: further evidence for an immune response. 
Psychiatry Res. 1994;54:143–60.
125.  Baig S, Halawa I, Qureshi GA. High performance liquid chromatog-
raphy as a tool in the deﬁ  nition of abnormalities in monoamine and 
tryptophan metabolites in cerebrospinal ﬂ  uid from patients with 
neurological disorders. Biomed Chromatogr. 1991;5:108–12.
126.  Smith RS. The macrophage theory of depression. Med Hypotheses. 
1991;35:298–306.
127.  Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. 
IDO and interferon-alpha-induced depressive symptoms: a shift in 
hypothesis from tryptophan depletion to neurotoxicity. Mol 
Psychiatry. 2005;10:538–44.
128.  Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen 
Hosp Psychiatry. 1987;9:426–34.
129.  Katon W, Sullivan MD. Depression and chronic medical illness. J 
Clin Psychiatry. 1990;51 Suppl 3–11;discussion 12–4.
130.  Riedel WJ, Klaassen T, Deutz NE, Van someren A, Van praag HM. 
Tryptophan depletion in normal volunteers produces selective impair-
ment in memory consolidation. Psychopharmacology (Berl). 
1999;141:362–9.
131.  Harmer CJ, Bhagwagar Z, Cowen PJ, Goodwin GM. Acute 
administration of citalopram facilitates memory consolidation in 
healthy volunteers. Psychopharmacology (Berl). 2002;163:106–10.
132.  Leblhuber F, Walli J, Jellinger K, et al. Activated immune system 
in patients with Huntington’s disease. Clin Chem Lab Med. 
1998;36:747–50.
133. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. 
Tryptophan degradation and immune activation in Alzheimer’s 
disease. J Neural Transm. 2000;107:343–53.
134.  Gendelman HE, Zheng J, Coulter CL, et al. Suppression of 
inﬂ  ammatory neurotoxins by highly active antiretroviral therapy in 
human immunodeﬁ  ciency virus-associated dementia. J Infect Dis. 
1998;178:1000–7.
135. Suarez S, Baril L, Stankoff B, et al. Outcome of patients with 
HIV-1-related cognitive impairment on highly active antiretroviral 
therapy. Aids. 2001;15:195–200.
136.  Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: 
immunosuppression by starvation? Immunol Today. 1999;20:469–73.
137.  Murray MF, Langan M, Macgregor RR. Increased plasma tryptophan 
in HIV-infected patients treated with pharmacologic doses of nico-
tinamide. Nutrition. 2001;17:654–6.
138.  Abrams B, Duncan D, Hertz-Picciotto I. A prospective study of dietary 
intake and acquired immune deﬁ  ciency syndrome in HIV-seropositive 
homosexual men. J Acquir Immune Deﬁ  c Syndr. 1993;6:949–58.
139.  Tang AM, Graham NM, Saah AJ. Effects of micronutrient intake on 
survival in human immunodeﬁ  ciency virus type 1 infection. Am J 
Epidemiol. 1996;143:1244–56.
140.  Muller AJ, Duhadaway JB, Donover PS, Sutanto-Ward E, Prendergast 
GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory 
target of the cancer suppression gene Binl potentiates cancer chemo-
therapy. Nat Med. 2005;11:312–9.
141. Foster AC, Willis CL, Tridgett R. Protection  Against N-methyl-D-aspartate 
Receptor-Mediated Neuronal Degeneration In Rat Brain by 7-chlo-
rokynurenate and 3-amino-l-hydroxypyrrolid-2-one, Antagonists at The 
Allosteric Site for Glycine. Eur J Neurosci. 1990;2:270–7.
142.  Hartley DM, Monyer H, Colamarino SA, Choi DW. 7-Chlorokynure-
nate Blocks NMDA Receptor-Mediated Neurotoxicity in Murine 
Cortical Culture. Eur J Neurosci. 1990;2:291–5.
143.  Rao TS, Gray NM, Dappen MS, et al. Indole-2-carboxylates, novel 
antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine 
recognition sites: in vivo characterization. Neuropharmacology. 
1993;32:139–47.
144.  Hokari M, Wu, HQ, Schwarcz R, Smith QR. Facilitated brain uptake 
of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid. 
Neuroreport. 1996;8:15–8.
145.  Wu HQ, Salituro FG, Schwarcz R. Enzyme-catalyzed production of 
the neuroprotective NMD A receptor antagonist 7-chlorokynurenic 
acid in the rat brain in vivo. Eur J Pharmacol. 1997;319:13–20.
146.  Wu HQ, Lee SC, Schwarcz R. Systemic administration of 4-chlo-
rokynurenine prevents quinolinate neurotoxicity in the rat hippocam-
pus. Eur J Pharmacol. 2000;390:261–74.
147.  Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active 
immunoregulator laquinimod (ABR-215062) effectively inhibits 
development and relapses of experimental autoimmune encephalo-
myelitis. J Neuroimmunol. 2002;130:163–72.
148.  Zou LP, Abbas N, Volkmann I, et al. Suppression of experimental 
autoimmune neuritis by ABR-215062 is associated with altered 
Thl/Th2 balance and inhibited migration of inﬂ  ammatory cells into 
the peripheral nerve tissue. Neuropharmacology. 2002;42:731–9.
149.  Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-
215062) suppresses the development of experimental autoimmune 
encephalomyelitis, modulates the Thl/Th2 balance and induces the 
Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol. 
2004;156:3–9.
150. Yang  Y,  Hentati  A, Deng HX, et al. The gene encoding alsin, a protein 
with three guanine-nucleotide exchange factor domains, is mutated 
in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 
2001;29:160–5.
151.  Polman C, Barkhof F, Sandberg-wollheim M, Linde A, Nordle O, 
Nederman T. Treatment with laquinimod reduces development of 
active MRI lesions in relapsing MS. Neurology. 2005;64:987–91.
152.  Williamson RA, Yea CM, Robson PA, et al. Dihydroorotate dehy-
drogenase is a high affinity binding protein for A77 1726 and 
mediator of a range of biological effects of the immunomodulatory 
compound. J Biol Chem. 1995;270:22467–72.
153.  O’connor PW, Li D, Freedman MS, et al. A Phase II study of the 
safety and efﬁ  cacy of teriﬂ  unomide in multiple sclerosis with relapses. 
Neurology. 2006;66:894–900.
154.  Suzawa H, Kikuchi S, Arai N, Koda A. The mechanism involved in 
the inhibitory action of tranilast on collagen biosynthesis of keloid 
ﬁ  broblasts. Jpn J Pharmacol. 1992;60:91–6.19
Kynurenine pathway metabolites in humans
International Journal of Tryptophan Research 2009:2 
155.  Isaji M, Miyata H, Ajisawa Y, Takehana Y, Yoshimura N. Tranilast 
inhibits the proliferation, chemotaxis and tube formation of human 
microvascular endothelial cells in vitro and angiogenesis in vivo. 
Br J Pharmacol. 1997;122:1061–6.
156.  Pellicciari R, Natalini B, Costantino G, et al. Modulation of the kynuren-
ine pathway in search for new neuroprotective agents. Synthesis and 
preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of 
kynurenine-3-hydroxylase. J Med Chem. 1994;37:647–55.
157.  Connick JH, Heywood GC, Sills GJ, Thompson GG, Brodie MJ, 
Stone TW. Nicotinylalanine increases cerebral kynurenic acid content 
and has anticonvulsant activity. Gen Pharmacol. 1992;23:235–9.
158.  Russi P, Alesiani M, Lombardi G, Davolio P, Pellicciari R, Moroni F. 
Nicotinylalanine increases the formation of kynurenic acid in the brain 
and antagonizes convulsions. J Neurochem. 1992;59:2076–80.
159.  Harris CA, Miranda AR, Tanguay JJ, Boegman RJ, Beninger RJ, 
Jhamandas K. Modulation of striatal quinolinate neurotoxicity by 
elevation of endogenous brain kynurenic acid. Br J Pharmacol. 
1998;124:391–9.
160.  Chiarugi A, Carpenedo R, Molina MT, Mattoli L, Pellicciari R, 
Moroni F. Comparison of the neurochemical and behavioral effects 
resulting from the inhibition of kynurenine hydroxylase and/or kyn-
ureninase. J Neurochem. 1995;65:1176–83.
161.  Chiarugi A, Moroni F. Quinolinic acid formation in immune-activated 
mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dime-
thoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesul fonamide (Ro 
61–8048), two potent and selective inhibitors of kynurenine hydrox-
ylase. Neuropharmacology. 1999;38:1225–33.
162.  Moroni F, Cozzi A, Carpendo R, Cipriani G, Veneroni O, Izzo E. 
Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentra-
tion in the extracellular spaces of the basal ganglia but not in those of 
the cortex or hippocampus. Neuropharmacology. 2005;48:788–95.
163.  Chiarugi A, Cozzi A, Ballerini C, Massacesi L, Moroni F. Kynurenine 
3-mono-oxygenase activity and neurotoxic kynurenine metabolites 
increase in the spinal cord of rats with experimental allergic enceph-
alomyelitis. Neuroscience. 2001;102:687–95.
164.  Clark CJ, Mackay GM, Smythe GA, Bustamante S, Stone TW, 
Phillips RS. Prolonged survival of a murine model of cerebral 
malaria by kynurenine pathway inhibition. Infect Immun. 
2005;73:5249–51.
165.  Werner ER, Fuchs D, Hausen A, et al. Tryptophan degradation in 
patients infected by human immunodeﬁ  ciency virus. Biol Chem 
Hoppe Seyler. 1988;369:337–40.
166.  Larsson M, Hagberg L, Norkrans G, Forsman A. Indole amine deﬁ  -
ciency in blood and cerebrospinal ﬂ  uid from patients with human 
immunodeﬁ  ciency virus infection. J Neurosci Res. 1989;23:441–6.
167.  Heyes MP, Saito K, Devinsky O, Nadi NS. Kynurenine pathway 
metabolites in cerebrospinal ﬂ  uid and serum in complex partial 
seizures. Epilepsia. 1994;35:251–7.
168.  Orlikov AB, Prakhye IB, Ryzov IV. Kynurenine in blood plasma and 
DST in patients with endogenous anxiety and endogenous depression. 
Biol Psychiatry. 1994;36:97–102.
169.  Fujigaki S, Saito K, Takemura M, et al. Species differences in L-
tryptophan-kynurenine pathway metabolism: quantiﬁ  cation of anthra-
nilic acid and its related enzymes. Arch Biochem Biophys. 
1998;358:329–35.
170.  Heyes MP, Saito K, Lackner A, Wiley CA, Achim CL, Markey SP. 
Sources of the neurotoxin quinolinic acid in the brain of HIV1-
infected patients and retrovirus-infected macaques. Faseb J. 
1998;12:881–96.
171.  Huengsberg M, Winer JB, Gompels M, Round R, Ross J, Shahmanesh M. 
Serum kynurenine-to-tryptophan ratio increases with progressive 
disease in HIV-infected patients. Clin Chem. 1998;44:858–62.
172.  Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-mersh 
TG. Serum tryptophan decrease correlates with immune activation 
and impaired quality of life in colorectal cancer. Br J Cancer. 
2002;86:1691–6.
173.  Ilzecka J, Kocki T, Stelmasiak Z, Turski WA. Endogenous protectant 
kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand. 
2003;107:412–8.
174.  Schrocksnadel K, Widner B, Bergant A, et al. Longitudinal study of 
tryptophan degradation during and after pregnancy. Life Sci. 
2003;72:785–93.
175.  Wirleitner B, Rudzite V, Neurauter G, et al. Immune activation and 
degradation of tryptophan in coronary heart disease. Eur J Clin Invest. 
2003;33:550–4.
176.  Schrocksnadel K, Winkler C, Fuith LC, Fuchs D. Tryptophan deg-
radation in patients with gynecological cancer correlates with immune 
activation. Cancer Lett. 2005;223:323–9.
177.  Forrest CM, Mackay GM, Oxford L, Stoy N, Stone TW, Darlington 
LG. Kynurenine pathway metabolism in patients with osteoporosis 
after 2 years of drug treatment. Clin Exp Pharmacol Physiol. 
2006;33:1078–87.
178.  Mackay GM, Forrest CM, Stoy N, et al. Tryptophan metabolism and 
oxidative stress in patients with chronic brain injury. Eur J Neurol. 
2006;13:30–42.
179.  Darlington LG, Mackay GM, Forrest CM, Stoy N, George C, Stone 
TW. Altered kynurenine metabolism correlates with infarct volume 
in stroke. Eur J Neurosci. 2007;26:2211–21.
180.  Hartai Z, Juhasz A, Rimanoczy A, et al. Decreased serum and red 
blood cell kynurenic acid levels in Alzheimer’s disease. Neurochem 
Int.2007;50:308–13.
181.  Schrocksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M, 
Fuchs D. Tryptophan degradation increases with stage in patients 
with rheumatoid arthritis. Clin Rheumatol. 2006;25:334–7.
182.  Chen Y, Stankovic R, Cullen KA, et al. The kynurenine pathway and 
inﬂ  ammation in amyotrophic lateral sclerosis. [Abstract]. Amyotroph 
Lateral Scler. Suppl. 1, 81.
183.  Young SN, Joseph MH, Gauthier S. Studies on kynurenine in human 
cerebrospinal ﬂ  uid: lowered levels in epilepsy. J Neural Transm. 
1983;58:193–204.
184.  Gisslen M, Larsson M, Norkrans G, Fuchs D, Wachter H, Hagberg L. 
Tryptophan concentrations increase in cerebrospinal ﬂ  uid and blood 
after zidovudine treatment in patients with HIV type 1 infection. 
AIDS Res Hum Retroviruses. 1994;10:947–51.
185.  Heyes MP, Saito K, Milstien S, Schiff SJ. Quinolinic acid in tumors, 
hemorrhage and bacterial infections of the central nervous system in 
children. J Neurol Sci. 1995;133:112–8.
186.  Medana IM, Hien TT, Day NP, et al. The clinical signiﬁ  cance of 
cerebrospinal ﬂ  uid levels of kynurenine pathway metabolites and 
lactate in severe malaria. J Infect Dis. 2002;185:650–6.
187.  Rejdak K, Bartosik-psujek H, Dobosz B, et al. Decreased level of 
kynurenic acid in cerebrospinal ﬂ  uid of relapsing-onset multiple 
sclerosis patients. Neurosci Lett. 2002;331:63–5.
188.  Nilsson LK, Linderholm KR, Engberg G, et al. Elevated levels of 
kynurenic acid in the cerebrospinal ﬂ  uid of male patients with schizo-
phrenia. Schizophr Res. 2005;80:315–22.
189.  Atlas A, Gisslen M, Nordin C, Lindstrom L, Schwieler L. Acute 
psychotic symptoms in HIV-1 infected patients are associated with 
increased levels of kynurenic acid in cerebrospinal ﬂ  uid. Brain Behav 
Immun. 2007;21:86–91.
190.  Beal MF, Matson WR, Storey E, et al. Kynurenic acid concentrations 
are reduced in Huntington’s disease cerebral cortex. J Neurol Sci. 
1992;108:80–7.
191.  Pearson SJ, Reynolds GP. Increased brain concentrations of a neu-
rotoxin, 3-hydroxykynurenine, in Huntington’s disease. Neurosci 
Lett. 1992;144:199–201.
192.  Sardar AM, Bell JE, Reynolds GP. Increased concentrations of the 
neurotoxin 3-hydroxykynurenine in the frontal cortex of HIV1-positive 
patients. J Neurochem. 1995;64:932–5.
193. Bara  H, Hainfellner JA, Kepplinger B, Mazal PR, Shchmid H, Budka. 
Kynurenic acid metabolism in the brain of HIV-1 infected patients. 
J Neural Transm. 2000;107:1127–38.